Business
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/37b8ce39cd94dc9a4e604f72ddc75a2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/867tm89bIelkfZIbJEXv.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/37b8ce39cd94dc9a4e604f72ddc75a2b","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sbLLExF0JhBYGAQw8MieiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/37b8ce39cd94dc9a4e604f72ddc75a2b","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Study Continuation Follows Review of Site Level Data and Recommendation of Data Monitoring Committee","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"BMS Remains Blinded to Study Data","length":33,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., December 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") today announced that it will enroll additional patients in the ADEPT-2 study. As part of its commitment to upholding the highest standards in clinical research and following a thorough blinded review of the ADEPT-2 study data, the company identified irregularities due to clinical trial execution at a small number of study sites. With these findings, prior to database lock, BMS made the decision to exclude patient data from those sites from the primary analysis. Following consultation and agreement with the U.S. Food and Drug Administration (FDA), an interim data analysis for efficacy and safety was conducted by an independent party and reviewed by the Data Monitoring Committee (DMC).","length":795,"tagName":"p"},{"type":"text","content":"Following this analysis, the DMC recommended the study continue by enrolling additional patients to the original target study population. Based on this recommendation, BMS will continue patient enrollment and advance the program as advised by the DMC. BMS remains blinded to study data.","length":286,"tagName":"p"},{"type":"text","content":""BMS agrees with the decision made in consultation with the FDA and DMC to continue the Phase 3 study and will move forward with recruiting additional patient...